[68Ga]Ga-DOTA-FAPI-04 PET/CT在腹膜癌评估中的作用及与[18F]-FDG PET/CT的比较
该回顾性研究纳入46例疑似腹膜恶性肿瘤患者,比较[68Ga]Ga-DOTA-FAPI-04与[18F]-FDG PET/CT对腹膜癌的评估效能。结果显示FAPI-04的SUV显著更高(中位SUV 3.48 vs. 9.82,P<0.001),PCI评分更高(6 vs. 18,P<0.001),灵敏度更优(72.09% vs. 97.67%,P=0.002)。
要点
- [68Ga]Ga-DOTA-FAPI-04 PET/CT对腹膜癌的灵敏度显著高于[18F]-FDG PET/CT。
- FAPI-04在腹膜癌病灶的SUV显著高于FDG,尤其胃癌来源腹膜癌。
- FAPI-04 PET/CT显示更高的PCI评分,提示可检测更大范围的病变。
核心结论
- [68Ga]Ga-DOTA-FAPI-04 PET/CT对多种癌症患者的腹膜癌检测灵敏度优于[18F]-FDG PET/CT,尤其在胃癌中。
- FAPI-04在腹膜癌的摄取显著高于FDG,显示病变范围更大并产生更高的PCI评分。
研究设计与样本
- 共纳入46例患者,包括16例弥漫型腹膜癌、27例结节型腹膜癌和3例真阴性患者。
主要发现
- 病灶中位SUV在[18F]-FDG与[68Ga]Ga-DOTA-FAPI-04 PET/CT间差异显著(3.48 vs. 9.82;P < 0.001)。
- 胃癌来源腹膜癌中位SUV差异显著(3.44 vs. 8.05;P = 0.001)。
- [68Ga]Ga-DOTA-FAPI-04 PET/CT的PCI评分高于[18F]-FDG PET/CT(6 vs. 18;P < 0.001)。
- [68Ga]Ga-DOTA-FAPI-04 PET/CT检测腹膜癌的灵敏度高于[18F]-FDG PET/CT(72.09% vs. 97.67%;P = 0.002)。
关键数值与推荐
- 腹膜癌病灶中位SUV:[18F]-FDG 3.48 vs. [68Ga]Ga-DOTA-FAPI-04 9.82(P < 0.001)。
- 胃癌腹膜癌中位SUV:[18F]-FDG 3.44 vs. [68Ga]Ga-DOTA-FAPI-04 8.05(P = 0.001)。
- PCI评分:[18F]-FDG 6 vs. [68Ga]Ga-DOTA-FAPI-04 18(P < 0.001)。
- 灵敏度:[18F]-FDG 72.09% vs. [68Ga]Ga-DOTA-FAPI-04 97.67%(P = 0.002)。
临床怎么用
- [68Ga]Ga-DOTA-FAPI-04 PET/CT可能提高腹膜癌检测的灵敏度,尤其在胃癌患者中。
- 更高的SUV和PCI评分可能增强图像对比度、提升诊断信心并减少漏诊比例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to explore the role of [68Ga]Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT), compared with 18F-fluorodeoxyglucose [18F]-FDG PET/CT, for evaluating peritoneal carcinomatosis in patients with various types of cancer. METHODS: Patients with suspected peritoneal malignancy, who underwent both [18F]-FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT between October 2019 and August 2020, were retrospectively analysed. The radiotracer uptake, peritoneal cancer index (PCI) score, and diagnostic performance of [18F]-FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT were evaluated and compared. RESULTS: Our cohort consisted of 46 patients, including 16 patients with diffuse-type peritoneal carcinomatosis, 27 with nodular-type peritoneal carcinomatosis, and 3 true-negative patients. A significant difference in standard uptake values (SUV) of lesions between [18F]-FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT examination was observed (median SUV: 3.48 vs. 9.82; P < 0.001), particularly in peritoneal carcinomatosis from gastric cancer (median SUV: 3.44 vs. 8.05; P = 0.001). Moreover, [68Ga]Ga-DOTA-FAPI-04 PET/CT showed a higher PCI score and better sensitivity than [18F]-FDG PET/CT for the detection of peritoneal carcinomatosis (6 vs. 18; P < 0.001; 72.09% vs. 97.67%; P = 0.002). CONCLUSION: [68Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated superior sensitivity over [18F]-FDG PET/CT for the detection of peritoneal carcinomatosis in patients with various types of cancer, particularly gastric cancer. Furthermore, the uptake of [68Ga]Ga-DOTA-FAPI-04 in peritoneal carcinomatosis was significantly higher than that of [18F]-FDG, demonstrating a larger extent of the lesions and yielding a higher PCI score. This could help enhance the image contrast, improve physicians' diagnostic confidence, and reduce the proportion of missed diagnoses.
引用
- Zhao L, Pang Y, Luo Z, et al. Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021. PMID: 33415432. doi:10.1007/s00259-020-05146-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。